EP300 and neoplasm: Importantly, similarly to what was seen in EP300 knockouts, ETC-159 treatment only minimally slowed down the GATA6-knockout tumor growth without reaching statistical significance, confirming that downregulating GATA6 conferred resistance to PORCN inhibition (Figure 4B and Figure 5E).